

New Evidence-Based Guideline— Gastroesophageal Cancer

A multidisciplinary perspective to improve patient outcomes

The College of American Pathologists (CAP), the American Society for Clinical Pathology (ASCP), and the American Society of Clinical Oncology (ASCO) collaborated to develop a clinical practice guideline that helps establish standard HER2 testing, improve the accuracy of the test interpretation, guide HER2-targeted therapies, and provide accurate, personalized care for patients with gastric cancer.

HER2 Testing and Clinical Decision Making in
Gastroesophageal Adenocarcinoma: Guideline
from the CAP-ASCP-ASCO

11

Evidence-based Recommendations

- 969 articles reviewed
- 116 studies included in the evidence synthesis



43,280

2016 gastroesophageal adenocarcinoma
cases diagnosed in US

22%

Patients with
gastroesophageal
cancers that are HER2+



HER2

Directed treatment
shown to improve the life
span of patients with
advanced gastric cancer

Bartley AN, Washington K, Ventura CB, et al. *HER2* testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology and the American Society of Clinical Oncology. *Arch Pathol Lab Med.* 2016;140(12):1345-1363. doi: [10.5858/arpa.2016-0331-CP](https://doi.org/10.5858/arpa.2016-0331-CP)



COLLEGE of AMERICAN
PATHOLOGISTS



STRONGERTOGETHER



American Society of Clinical Oncology